Related Experiment Videos
beta-Adrenoreceptor blockage and genetic hypertension development in rats
Clinical and Experimental Hypertension
|January 1, 1980
Summary
Beta-blockers propranolol and atenolol effectively reduced genetic hypertension in rats by lowering cardiac output. Acebutolol was ineffective, suggesting drug-specific effects on cardiovascular structure.
Area of Science:
- Pharmacology
- Cardiovascular Physiology
- Hypertension Research
Background:
- Spontaneously hypertensive rats (SHRs) are a key model for studying genetic hypertension.
- Beta-adrenergic blocking agents are widely used to manage hypertension.
- Understanding the mechanisms by which beta-blockers affect hypertension development is crucial.
Purpose of the Study:
- To investigate the effects of propranolol, atenolol, and acebutolol on genetic hypertension development in SHRs.
- To analyze the impact of these drugs on hemodynamic parameters and cardiac remodeling.
- To explore the relationship between beta-adrenergic blockade, hemodynamic changes, and hypertension prevention.
Main Methods:
- Daily oral administration of propranolol, atenolol, and acebutolol to SHRs from 6 to 20 weeks of age.
- Regular monitoring of heart rate (HR), cardiac output (CO), stroke volume (SV), peripheral resistance (PR), plasma renin concentration (PRC), and heart weight/body weight ratio (HW/BW).
- Assessment of genetic hypertension development (GHD) throughout the study period.
Main Results:
- Propranolol and particularly atenolol significantly inhibited GHD, while acebutolol showed no effect.
- No correlation was observed between GHD prevention and the degree of beta-adrenergic blockade, reduction in HR/CO, or decrease in PRC.
- Propranolol and atenolol opposed GHD primarily by reducing CO, though atenolol's effect was partly offset by increased PR. Acebutolol's ineffectiveness was linked to a PR increase that counteracted CO reduction.
Conclusions:
- Propranolol and atenolol demonstrate efficacy in preventing genetic hypertension development in SHRs, mainly through cardiac output reduction.
- Acebutolol's lack of efficacy suggests that its effects on peripheral resistance may negate any potential benefits.
- Differential responses to these beta-blockers likely stem from distinct early structural adaptations in the cardiovascular system.